MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Johnson & Johnson Depreciation & Amortization 2011-2026 | JNJ
Annual Depreciation & Amortization Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.5 B | 7.34 B | 7.49 B | 7.39 B | 7.23 B | - | 7.01 B | 6.93 B | 5.64 B | 3.75 B | - | 3.9 B | 4.1 B | 3.67 B | 2.94 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.5 B | 2.94 B | 5.76 B |
Quarterly Depreciation & Amortization Johnson & Johnson
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 B | 1.3 B | 1.77 B | 1.2 B | 1.1 B | 1.82 B | 1.1 B | 1.1 B | 1.88 B | - | 1 B | 1.1 B | 1.77 B | - | 5.55 B | 1.2 B | 1.89 B | - | 5.29 B | 3.47 B | 1.75 B | - | 5.19 B | 3.47 B | 1.76 B | - | 5.19 B | 3.46 B | 1.75 B | - | 3.77 B | 2.06 B | 912 M | - | 2.7 B | 1.79 B | 891 M | - | 2.71 B | 1.78 B | 895 M | - | 2.9 B | 1.96 B | 1.01 B | - | 3 B | 2.03 B | 1.04 B | - | 2.63 B | 1.62 B | 773 M | - | 2.32 B | 1.53 B | 755 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.55 B | 755 M | 2.12 B |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.57 | 0.04 % | $ 3.74 B |  USA |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.41 | -1.4 % | $ 363 M | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | USA |
 |
Aytu BioScience
AYTU
|
5.38 M | $ 2.56 | -3.76 % | $ 16.1 M | USA |
 |
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 20.87 | 2.3 % | $ 976 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
548 K | $ 4.17 | -0.24 % | $ 446 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.57 | -0.16 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
1.65 M | $ 3.17 | 2.59 % | $ 319 M | USA |
 |
Codiak BioSciences
CDAK
|
5.34 M | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 2.93 | -4.87 % | $ 6.38 B | Israel |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Celldex Therapeutics
CLDX
|
3.38 M | $ 33.62 | 3.73 % | $ 2.23 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
1.48 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.92 | 1.03 % | $ 264 B |  Britain |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
292 K | - | -6.63 % | $ 13.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |